MOTS-C: Multi-field Scientific Applications and Potential of Mitochondrial-Derived Peptides

Dec 10, 2025

Leave a message

Knowledge Content

 

In the field of metabolic disease intervention, MOTS-C is a core research target. It can enhance skeletal muscle glucose uptake and lipid oxidation by inhibiting the folate cycle and activating the AMPK pathway. In a type 2 diabetes model, it can reduce fasting blood glucose and glycated serum protein levels, while improving myocardial ultrastructural damage. For gestational diabetes, it can alleviate maternal hyperglycemia, improve insulin sensitivity, protect pancreatic β-cells from damage, and reduce the risk of overweight and death in offspring. The latest research in 2025 also confirmed that it can delay the aging of pancreatic β-cells by inhibiting the mTORC1 pathway and glutamine breakdown, thereby delaying the progression of diabetes and providing new ideas for "aging-targeted therapy" of diabetes.https://www.fiercerawsource.com/peptides/premium-high-purity-peptides-mots-c.html

 

Anti-aging and maintaining homeostasis are another important application area for MOTS-C. MOTS-C expression levels decline significantly with age; supplementation can activate the Nrf2 antioxidant pathway, inhibit the NF-κB inflammatory pathway, improve muscle homeostasis and motor function in aged mice, and reverse age-related metabolic decline. Simultaneously, it can cross the blood-brain barrier, reducing neurological deficits and inhibiting brain inflammatory pathways in traumatic brain injury models, demonstrating neuroprotective potential.

 

In the fields of antiviral therapy and organ protection, the role of MOTS-C has been newly discovered in recent years. Studies show that MOTS-C levels in patients with chronic hepatitis B are negatively correlated with HBV DNA load. It can inhibit viral replication by mediating mitochondrial remodeling and activating antiviral signaling pathways, providing a new target for hepatitis B diagnosis and treatment. Furthermore, it can reduce pulmonary ferroptosis by regulating the PPAR-γ pathway, playing a protective role against acute lung injury caused by ischemia-reperfusion and improving pulmonary oxygenation.

 

It should be noted that MOTS-C is still in the preclinical research stage, and its human dosage and long-term safety have not yet been determined. However, as a key molecule connecting mitochondrial function and multisystem diseases, it has become an important research tool and potential therapeutic peptide for metabolic diseases and aging-related diseases.

 

2

 

 
Send Inquiry
Auctus Steroid Pharma Co., Ltd
Provide a complete after-sales service guarantee, including product return and exchange policies, quality assurance, etc.
contact us